← Eichor
Study identifier: NCT07255859 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

AVIGA3 (Cohort 2.0)

Condition: Maculopathy  ·  Sponsor: Tan Tock Seng Hospital

PhaseNA
Planned participants60
Who can joinAll sexes, 50 Years to 99 Years
Healthy volunteersNo

About this study

Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central vision. It is estimated that the prevalence of early and late AMD in Asian populations aged 40 to 79 were 6.8% and 0.56% respectively. Prevalence in white populations estimated from large population studies were 8.8% and 0.59% respectively. With the aging population and people living longer, these numbers will only increase. Hence, this study aims to develop a system to evaluate the AVIGA system through remote monitoring for disease recurrence of wet aged-related macular degeneration using eye gaze tracking.

This description comes directly from the study's public registry record.

Talk to the study team

Zheng Kuang, Noel Soh, BSc  ·  +65 6357 3693  ·  zheng.Kuang.soh@nhghealth.com.sg

Always discuss trial participation with your own doctor first.

Locations (1)

Tan Tock Seng HospitalSingapore, SingaporeRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07255859